12:00 AM
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Nalbuphine ER: Phase I started

Trevi began an open-label, dose-escalation Phase I trial to evaluate oral Nalbuphine ER in 12 patients with end-stage renal disease and 8 healthy volunteers. Trevi plans to begin a Phase II/III trial in uremic pruritus in...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >